Immatics and Bristol Myers Squibb (BMS) have expanded their strategic partnership to develop multiple allogeneic TCR-T and/or CAR-T programmes. As per the agreement, both companies will develop two programmes owned by BMS with an option to developan additional four programmes each. Programmes under the agreement will utilise Immatics’ gamma delta T cell-derived, allogeneic adoptive cell therapy (ACT) platform, called ACTallo®. The deal aligns with BMS’ strategy to collaborate and develop next generation cell therapies for the treatment of patients with cancer.